Skip to content

Oruka Therapeutics, Inc. ORKA Investment Proceeds

Investment Proceeds at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$133.86M+0.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$156.69M+38.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$50.82M-25.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
$100.83M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$79.38M+1,384%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$107.75M+50.9%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s investment proceeds?
Oruka Therapeutics, Inc. (ORKA) reported investment proceeds of $76.47M in Q1 2026.
How has Oruka Therapeutics, Inc.'s investment proceeds changed year-over-year?
Oruka Therapeutics, Inc.'s investment proceeds decreased by 12.3% year-over-year, from $87.17M to $76.47M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.